Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Inclusion Criteria:

1. Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson etal, 2018).

2. Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.

3. Evidence of recent MS activity as defined by the study protocol.

4. Neurologically stable subject, with no relapse for ≤ 28 days before randomization.

Exclusion Criteria:

1. Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).

2. Multiple sclerosis disease duration of ≥ 10 years in Participants with ExpandedDisability Status Scale (EDSS) score of ≤ 2.5 at screening.

3. Any contraindications to study procedures or medications as outlined in the studyprotocol.

4. Any prohibited medication as defined in the study protocol.

5. Any significant concomitant disease that may require chronic treatment with systemiccorticosteroids and/or systemic immunosuppressants during the study.

6. Current or history of any significant medical conditions as described in the studyprotocol.

7. Any abnormal laboratory blood values as defined in the study protocol.